Association between p53 Arg72Pro polymorphism and colorectal cancer risk: A meta-analysis

Onkologie

Volumn 33, Issue 12, 2010, Pages 666-674

  Economopoulos, Konstantinos P ^a,b   Sergentanis, Theodoros N ^a,b   Zagouri, Flora ^b   Zografos, George C ^b  

^a Society of Junior Doctors   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Colorectal cancer; Meta analysis; p53 Arg72Pro polymorphism; p53 codon 72 polymorphism

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CHINESE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENETIC ASSOCIATION; HUMAN; META ANALYSIS; PUBLICATION; RACE DIFFERENCE; STRATIFICATION; SYSTEMATIC REVIEW;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CODON; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649959529     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322210     Document Type: Article

References (57)

1. Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S: Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 2006;130:73-79.
2. Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: Cancer implications. Nat Rev Cancer 2009;9:95-107.
3. Zhang Z, Wang M, Wu D, Tong N, Tian Y: p53 codon 72 polymorphism contributes to breast cancer risk: A meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 2010;120:509-517.
4. Dai S, Mao C, Jiang L, Wang G, Cheng H: p53 polymorphism and lung cancer susceptibility: A pooled analysis of 32 case-control studies. Hum Genet 2009;125:633-638.
5. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT: p53 codon 72 polymorphism and gastric cancer: A meta-analysis of the literature. Int J Cancer 2007;121:1481-1486.
6. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, et al.: tp53 codon 72 polymorphism and cervical cancer: A pooled analysis of individual data from 49 studies. Lancet Oncol 2009;10:772-784.
7. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckman G: p53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16:1461-1464.
8. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F: A tp53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of tp53 mRNA. Oncogene 2004;23:1954-1956.
9. Perez LO, Abba MC, Dulout FN, Golijow CD: Evaluation of p53 codon 72 polymorphism in adeno carcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;12:1426-1429.
10. Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V, Ciferri E, Percivale P, Bianchi Scarra G, Nasti S, Fronza G, Varesco L: Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion 2006;74:228-235.
11. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G: Association of the tp53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007;37:385-390.
12. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J: Genetic polymorphisms in tp53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: Evidence for gene-environment interaction? Pharmacogenet Genomics 2007;17:639-645.
13. Mammano E, Belluco C, Bonafe M, Olivieri F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C, Lise M, Nitti D: Association of p53 polymorphisms and colorectal cancer: Modulation of risk and progression. Eur J Surg Oncol 2009;35:415-419.
14. Polakova V, Pardini B, Naccarati A, Landi S, Slyskova J, Novotny J, Vodickova L, Bermejo JL, Hanova M, Smerhovsky Z, et al.: Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat 2009;30:661-668.
15. Dakouras A, Nikiteas N, Papadakis E, Perakis M, Valis D, Rallis G, Tzanakis N, Peros G, Tsigkris C, Kittas C, Karakitsos P: p53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res 2008;28:1039-1043.
16. Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, Park WS: The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009;56:114-118.
17. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ: p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006;119:1863-1868.
18. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ: Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in tp53. Int J Cancer 2006;118:2479-2484.
19. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G: Characterization of a frequent polymorphism in the coding sequence of the tp53 gene in colonic cancer patients and a control population. Hum Genet 1991;86:369-370.
20. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N: p53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001;109:25-34.
21. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, et al.: No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181:81-85.
22. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A: Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004;6:529-535.
23. Lima JM, Serafim PV, Silva ID, Forones NM: [Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer]. Arq Gastroenterol 2006;43:8-13.
24. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, Feher G, Horvath OP, Ember I, Kiss I: GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 2008;28:1917-1922.
25. Wang NM, Tsai CH, Yeh KT, Chen SJ, Chang JG: p53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the Chinese. Int J Mol Med 1999;4:249-252.
26. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S: Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-1089.
27. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H: Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996;17:261-264.
28. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A: p53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer 2010;47:31-34.
29. Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA, Siddiqi MA: tp53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res 2010;9:651-660.
30. Grunhage F, Jungck M, Lamberti C, Berg C, Becker U, Schulte-Witte H, Plassmann D, Rahner N, Aretz S, Friedrichs N, et al.: Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis 2008;23:147-154.
31. Webb EL, Rudd MF, Sellick GS, El Galta R, Bethke L, Wood W, Fletcher O, Penegar S, Withey L, Qureshi M, et al.: Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. Hum Mol Genet 2006;15:3263-3271.
32. Kruger S, Bier A, Engel C, Mangold E, Pagenstecher C, von Knebel Doeberitz M, Holinski-Feder E, Moeslein G, Schulmann K, Plaschke J, et al.: The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J Med Genet 2005;42:769-773.
33. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, De La Chapelle A: p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-6844.
34. Economopoulos KP, Sergentanis TN: GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: A comprehensive meta-analysis. Eur J Cancer 2010;46:1617-1631.
35. Economopoulos KP, Sergentanis TN: XRCC3 Thr241Met polymorphism and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;121:439-443.
36. Economopoulos KP, Sergentanis TN: Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;121:545-551.
37. Economopoulos KP, Sergentanis TN: Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: A meta-analysis. Breast Cancer Res Treat 2010;120:211-216.
38. Sergentanis TN, Economopoulos KP: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;122:459-469.
39. Sergentanis TN, Economopoulos KP: GSTT1 and GSTP1 polymorphisms and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;121:195-202.
40. Sergentanis TN, Economopoulos KP: Association of two CASP8 polymorphisms with breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010;120:229-234.
41. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009;62: e1-e34.
42. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
43. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
44. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J: A method for meta-analysis of molecular association studies. Stat Med 2005;24:1291-1306.
45. Rohlfs RV, Weir BS: Distributions of Hardy-Weinberg equilibrium test statistics. Genetics 2008;180:1609-1616.
46. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ: MDM2 SNP309 T>G alone or in combination with the tp53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 2007;120:563-565.
47. Jia HR, He XL, Zhu ZZ, Jin XX, Wang AZ, Huang HY, Zhu J, Yu GB, Zhu GS: [tp53 gene polymorphisms and colorectal cancer risk in Chinese population]. Zhonghua Yi Xue Za Zhi 2007;87:1448-1451.
48. Zhu ZZ, Liu B, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu GS: Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 2008;9:847-852.
49. Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC: Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006;118:1790-1797.
50. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-5849.
51. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S: tp53 Arg72Pro polymorphism and colorectal cancer risk: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:1840-1847.
52. Tang NP, Wu YM, Wang B, Ma J: Systematic review and meta-analysis of the association between p53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol 2010;36:431-438.
53. Vickers A, Goyal N, Harland R, Rees R: Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998;19:159-166.
54. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP: Local literature bias in genetic epidemiology: An empirical evaluation of the Chinese literature. PLoS Med 2005;2: e334.
55. Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2008. www.cochranehandbook.org (last accessed: May 31, 2010).
56. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I: Dissemination and publication of research findings: An updated review of related biases. Health Technol Assess 2010;14: III, IX-XI, 1-193.
57. Lau J, Ioannidis JP, Schmid CH: Summing up evidence: One answer is not always enough. Lancet 1998;351:123-127.